Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENOPUR and REKOVELLE in Women Undergoing ART
2022-500308-23-00Phase 4Authorised
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, single-blind trial of recombinant human follicle stimulating hormone and menotropins in female infertility (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Number of fertilised (2 pronuclei [2PN]) oocytes. Planned start Nov 2022; status: authorised.
02
Drugs
recombinant human follicle stimulating hormonemenotropins
03
Conditions
female infertility
Beyond the preview
Go deeper on 2022-500308-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500308-23-00.